A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Status:
Recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Phase 1/Phase 2

Bolt Biotherapeutics, Inc.

Bristol-Myers Squibb

Nivolumab
Pembrolizumab